Search
Ramosetron
go.drugbank.com/drugs/DB09290InvestigationalIt is believed to have higher potency and longer antiemetic action than other 1st generation 5-HT3 antagonists such as ondansetron.
Indopan
go.drugbank.com/drugs/DB01446ExperimentalIllicitIt was developed in the 1960's by Upjohn with the intention for use as an antidepressant. In the 1990's, indopan became regulated as a Schedule I controlled substance in the United states.
ATX-201
go.drugbank.com/drugs/DB05765InvestigationalIt is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis.
Col-118
go.drugbank.com/drugs/DB05778InvestigationalIt is a believed to reduce erythema by constricting enlarged blood vessels in facial tissue.
1alpha,24S-Dihydroxyvitamin D2
go.drugbank.com/drugs/DB06117ExperimentalIt is developed for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD). Studies have shown LR-103 has the same potency as calcitriol, but much lower toxicity.
J147
go.drugbank.com/drugs/DB13957Experimental[A31606,A31607,A31608] It is a curcumin derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of neurodegenerative conditions associated with aging
Synonyms: N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-[(E)-(3-methoxyphenyl)methylene]acetohydrazideOAV201
go.drugbank.com/drugs/DB17842ExperimentalIt was first developed by Novartis and investigated for the treatment of Rett syndrome, but further investigation in clinical trials was halted.[L46661]
Elagolix
go.drugbank.com/drugs/DB11979ApprovedInvestigationalIt has been determined that endometriosis is one of the most common gynecologic disorders in the United States [A35868, A35869, F801].
PSN9301
go.drugbank.com/drugs/DB05001ExperimentalPSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for meal-related dosing.